Will Sovaldi and Harvoni pass the first gateway for insurance benefit?

Published: 2016-03-25 11:11:51

Updated: 2016-03-25 11:11:51

The health insurance benefit evaluation scheme of the Gilead’s hepatitis C treatments, Sovaldi(sofosbuvir) and Harvoni(sofosbuvir, ledipasvir) will finally be proposed at the Drug Benefit Deliberation Committee, Health Insurance Review & Assessment Service(HIRA), today(24^th).

It has been 5 months since they were introduced on September and October in 2015. Considering the fact the HIRA has re...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.